A pilot study of autologous bone marrow transplantation followed by recombinant interleukin-2 in malignant lymphomas

Leukemia and Lymphoma

Volumn 21, Issue 1-2, 1996, Pages 107-114

  Vey, Norbert ^a   Blaise, Didier ^a   Tiberghien, Pierre ^b   Attal, Michel ^c   Pico, José Luis ^d   Reiffers, Josy ^e   Harrousseau, Jean Luc ^f   Fiere, Denis ^g   Tabilio, Antonio ^h   Gabus, Raul ^a   Brandely, Maud ⁱ   Maraninchi, Dominique ^a  

^a INSTITUT PAOLI CALMETTES   (France)

^b UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^c CHU PURPAN   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e HAUT LÉVÊQUE HOSPITAL   (France)

^f HÔTEL DIEU   (France)

^g EDOUARD HERRIOT HOSPITAL   (France)

^h UNIVERSITY OF PERUGIA   (Italy)

ⁱ SANOFI   (France)

Author keywords

Autologous bone marrow; High dose chemotherapy; Hodgkin's disease; Interleukin 2; Non Hodgkin's lymphoma; Transplantation

Indexed keywords

CYCLOPHOSPHAMIDE; RECOMBINANT INTERLEUKIN 2;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; ERYTHEMA; FEMALE; FEVER; HEART ARRHYTHMIA; HODGKIN DISEASE; HUMAN; HYPERBILIRUBINEMIA; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; LUNG EDEMA; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NONHODGKIN LYMPHOMA; OLIGURIA; PERICARDITIS; PRIORITY JOURNAL; PRURITUS; SEPTICEMIA; THROMBOCYTOPENIA; VOMITING;

EID: 13344287037     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199609067587     Document Type: Article

References (36)

1. Philip, T., Armitage, J. O., Spitzer, G., Chauvin, F., Jagannath, S., Cahn, J. C. P., Goldstone, A., Gorin, N., Flesh, M., Laporte, J. M. D., Pico, J., Bosly, A., Anderson, C., Schots, R., Biron, P., Cabanillas, F. and Dicke, K. (1987) High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non Hodgkin's lymphoma. N. Engl. J. Med., 316, 1493-1498.
2. Jagannath, S., Armitage, J. O., Dicke, K. A., Tucker, S. L., Velasquez, W. S., Smith, K., Vaughan, W. P., Kessinger, A., Horwitz, L. J., Hagemeister, F. B., McLaughlin, P., Cabanillas, F. and Spitzer, G. (1989) Pronostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. J. Clin. Oncol., 7, 179-185.
3. Armitage, J. O., Jagannath, S., Spitzer, G., Bierner, P., Kersinger, A., Kumar, P., Cabanillas, F., Zander, A., Vellekoop, L. and Dicke, K. A. (1988) High-dose chemotherapy and autologous bone marrow transplantation as salvage treatment for patients with diffuse large cell lymphoma. Europ. J. Cancer Clin. Oncol., 22, 871-877.
4. Mills, W., Chopra, R., McMillan, A., Linch, D. C. and Goldstone, A. H. (1995) BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non Hodgkin's lymphoma. J. Clin. Oncol., 13, 588-595.
5. Surbone, A., Armitage, J. O. and Gale, R. P. (1991) Autotransplantation in lymphoma: better therapy or healthier patients? Ann. Intern. Med., 114, 1059-1060, (editorial).
6. Jones, R.J., Ambinder, R. F., Piantadosi, S. and Santos, G.W. (1991) Evidence of a graft versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood, 77, 649-653.
7. Ratanatharathorn, V., Uberti, J., Karanes, C., Abella, E., Lum, L. G., Momin, F., Cummings, G. and Sensenbrenner, L. L. (1994) Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non Hodgkin's lymphoma. Blood, 84, 1050-1055.
8. Weiden, P. L., Flournoy, N., Thomas, E. D., Prentice, R., Fefer, A., Buckner, C. and Storb, R. (1979) Antileukemic effect of graft versus host disease in human recipients of allogeneic marrow grafts. N. Engl. J. Med. 300, 1068-1070.
9. Morgan, D. A., Ruscetti, F. W. and Gallo, R. W. (1976) Selective in vitro growth of lymphocytes from normal human bone marrow. Science, 193, 1007-1011.
10. Rosenberg, A., Lotze, M. T., Muul, L. M., Chang, A., Avis, F., Leitman, S., Linehan, M., Robertson, L., Lee, R., Rubin, J., Seipp, C., Simpson, C. and White, D. (1987) A progress report on the treatment of 157 patients with advanced cancer using activated killer cells and interleukine-2 or high dose interleukine-2 alone. N. Engl. J. Med., 316, 889-897.
11. Maraninchi, D., Blaise, D., Viens, P., Brandely, M., Olive, D., Lopez, M., Sainty, D., Marit, G., Stoppa, A. M., Reiffers, J., Gratecos, N., Bertau-Perez, P., Mannoni, P., Mawas, C., Hercend, T., Sebahoun, G. and Carcassonne, Y. (1991) High-dose recombinant interleukine-2 and acute myeloid leukemias in relapse. Blood, 78, 2182-2187.
12. Gisselbrecht, C., Maraninchi, D., Pico, J. L., Milpied, N., Coiffier, B., Divine, M., Tiberghien, P., Bosly, A., Tilly, H., Boulat, O. and Brandely, M. (1994) Interleukin-2 treatment in lymphoma: a phase II multicenter study. Blood, 83, 2081-2085.
13. Allison, M. A., Jones, S. E. and Mc Guffy, P. (1989) Phase II trial of outpatient interleukin-2 in malignant lymphoma, chronic lymphocytic leukemia and selected solid tumor. J. Clin. Oncol., 7, 75-80.
14. Bernstein, Z. P., Vaikus, L., Friedman, N., Goldrosen, M. H., Watanabe, M., Rahman, E., Arbuck, S. G., Sweeney, J., Fesper, D., Henderson, E. D., Zeffren, J., Dennin, R. A., Levitt, D. and Foon, A. (1991) Interleukin-2 lymphokine activated killer cells therapy of non Hodgkin's lymphoma and Hodgkin's disease. J. Immunother., 10, 141-146.
15. Weber J. S., Yang, J. C., Topalian, S. L., Schwarzentruber, D. J., White, D. E. and Rosenberg, S. A. (1992) The use of interleukin-2 and lymphokine activated killer cells for treatment of patients with non Hodgkin's lymphoma. J. Clin. Oncol., 10, 33-40.
16. Lim, S. H., Worman, C. P., Callaghan, T., Jewell, A., Smith, M. P. and Goldstone, A. H. (1991) Continuous intravenous infusion of high-dose recombinant interleukin-2 for advanced lymphomas. A phase II study. Leukemia Research, 15 (6), 435-440.
17. Singer, C. R. J., Tansey, P. J. and Burnett, A. K. (1983) T lymphocyte reconstitution following autologous bone marrow transplantation. Clin. Exp. Immunol., 51, 455-460.
18. Charmot, D., Ragueneau, M., Olive, D., Maraninchi, D. and Mawas, C. (1987) Generation of CD8 cytolytic T cells early after autologous or allogeneic bone marrow transplantation. Bone Marrow Transplantation, 2, 183-194.
19. Reittie, J. E., Gottlieb, D., Heslop, H. E., Leger, O., Drexler, H. G., Hazlehurst, G., Hoffbrand, A. V., Prentice, H. G. and Brenner, M. K. (1989) Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. Blood, 73, 1351-1358.
20. Higuchi, C. M., Thompson, J. A., Cox, T., Lindgren, C. G., Buckner, C. D. and Fefer, A. (1989) Lymphokin-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies. Cancer Res., 49, 5509-5513.
21. Hercend, T., Takvorian, T., Nowill, A., Tantravahi, R., Moingeon, P., Anderson, K. C., Murray, C., Bohuon, C., Ythier, A. and Ritz, J. (1986) Characterization of natural killer cells with antileukemia activity following allogeneic bone marrow transplantation. Blood, 67, 722-728.
22. Truitt, R. L., Lefever, A. V. and Shih, C. Y. (1988) Analysis of effector cells in the graft versus leukemia reaction and their relation to graft versus host disease. T-cell depletion in allogeneic bone marrow transplantation. In Proceedings of the Serono symposia. Ares-Serono Symposia, Rome, Italy, edited by M. F. Martelli, F. Grignani, Y. Reisner, p73.
23. Welte, K., Ciobanu, N., Moore, M. A. S., Gulati, S., O'Reilly, R. J. and Mertelsmann, R. (1984) Defective interleukin-2 production in patients after bone marrow transplantation and in vitro restoration of defective T lymphocyte proliferation by highly purified interleukin-2. Blood, 64, 380-385.
24. Biaise, D., Olive, D., Stoppa, A. M., Pourreau, C., Lopez, M., Attal, M., Jasmin, C., Monges, G., Mawas, C., Mannoni, P., Palmer, P., Francks, C., Philip, T. and Maraninchi, D. (1990) Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation. Blood, 76, 1092-1097.
25. Blaise, D., Viens, P., Olive, D., Stoppa, A. M., Gabert, J., Pourreau, C., Attal, M., Gaspard, M. H., Mannoni, P., Jasmin, C., Palmer, P., Francks, C., Michel, G., Mawas, C., Baume, D., Philip, T. and Maraninchi, D. (1991) Recombinant interleukin-2 (rIL-2) after autologous bone marrow transplantation (BMT): a pilot study in 19 patients. Eur. Cytokine. Net., 2, 121-129.
26. Gottlieb, D. J., Brenner, M. K., Heslop, H. E., Bianchi, A. C. M., Bello-Fernandez, C., Mehta, A. B., Newland, A. C., Galazka, A. R., Scott, E. M., Hoffbrand, A. V. and Prentice, H. G. (1989) A phase I clinical trial of recombinant interleukin-2 following high-dose chemo-radiotherapy for hematological malignancy: applicability to the elimination of minimal residual disease. Br. J. Cancer, 60, 610-615.
27. Soiffer, R. J., Murray, C., Cochran, K., Cameron, C., Wang, E., Schow, P. W., Daley, J. F. and Ritz, J. (1992) Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell depleted allogeneic bone marrow transplantation. Blood, 79, 517-526.
28. Philip, T., Chauvin, F., Armitage, J., Bron, D., Hagenbeek, A., Biron, P., Spitzer, G., Velasquez, W., Weisenburger, D. D., Fernandez-Ranada, J., Somers, R., Rizzoli, V., Harousseau, J. L., Sotto, J. J., Cahn, J. Y., Guilhot, F., Biggs, J., Sonneveld, P., Misset J.L., Manna, A., Jagannath, S., Guglielmi, C., Chevreau, C., Delmer, A., Santini, G. and Coiffier, B. (1991) Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation. Blood, 77, 1587-1592.
29. Kaplan, E. L. and Meier, P. (1958) Non parametric estimation from incomplete observations. J. Am. Statis. Assoc., 53, 157-181.
30. Manzel, N. (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep., 50, 163-168.
31. Blaise, D., Stoppa, A. M., Viens, P., Sainty, D., Fossat, C., Miquel, M., Olive, D., Bouabdallah, R., Gabert, J., Baume, D. and Maraninchi, D. (1992) Intensive immunotherapy with recombinant interleukin-2 after autologous bone marrow transplantation is associated with a high incidence of bacterial infections. Bone marrow Transplantation, 10, 193-195
32. Higushi, C. M., Thompson, J. A., Petersen, F. B., Buckner, C. D. and Fefer, A. (1991) Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. Blood, 77, 2561-2563.
33. Weisdorf, D. J., Anderson, P. M., Blazar, B. R., Uckun, F. M., Kersey, J. H. and Ramsay, N. K. (1993) Interleukin-2 immediately after autologous bone marrow transplantation for acute lymphoblastic leukemia. A phase I study. Transplantation, 55, 61-66.
34. Gibbon, J. G., Linch, D. C., Singer, C. R., McMiller, A. K., Jarrett, M. and Goldstone, A. H. (1989) Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood, 73, 340-344.
35. Rapoport, A. P., Rowe, J. M., Kouides, P. A., Duerst, R. A., Abboud, C. N., Liesveld, J. L., Packman, C. H., Eberly, S., Sherman, M., Tanner, M. A., Constine, L. S. and Dipersio, J. F. (1993) One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome. J. Clin. Oncol., 11, 2351-2361.
36. Fefer, A., Benyunes, M. C., Massumoto, C., Higuchi, C., York, A., Buckner, C. D. and Thompson, J. A. (1993) Interleukin-2 therapy after autologous bone marrow transplantation for hematologic malignancies. Sem. Oncol., 6, (Suppl 9): 41-45.